Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 301–400 of 3,959
Vetrani, C., Calabrese, I., Cavagnuolo, L., Pacella, D., Napolano, E., Rienzo, S. D., Riccardi, G., Rivellese, A. A., Annuzzi, G., & Bozzetto, L. (2021) · Diabetologia · doi:10.1007/s00125-021-05587-0 · Cited by 57
Vitamin C supplementation for diabetes management: A comprehensive narrative review
Mason, S. A., Parker, L., van der Pligt, P., & Wadley, G. D. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.003 · Cited by 53
Cherubini, V., Bonfanti, R., Casertano, A., Nitto, E. D., Iannilli, A., Lombardo, F., Maltoni, G., Marigliano, M., Bassi, M., Minuto, N., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0031 · Cited by 55
“7 There are four metrics from CGM that are of clinical value for PWD and health care professionals as they are reflective of diabetes management in clinical practice.”
InfluentialReddy, N., Verma, N., & Dungan, K. M. (2020) · MDText.com, Inc. eBooks · Cited by 108
Severe Hypoglycemia: Is It Still a Threat for Children and Adolescents With Type 1 Diabetes?
Urakami, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00609 · Cited by 59
Self-citationKamrath, C., Tittel, S. R., Kapellen, T. M., von dem Berge, T., Heidtmann, B., Nagl, K., Menzel, U., Pötzsch, S., Konrad, K., & Holl, R. W. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30339-4 · Cited by 53
Foreman, Y. D., van Doorn, W. P. T. M., Schaper, N. C., van Greevenbroek, M. M. J., Kallen, C., Henry, R. M. A., Koster, A., Eussen, S. J. P. M., Wesselius, A., Reesink, K. D., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05474-8 · Cited by 53
Chun, K., Oh, J., Lee, C. J., Park, J. J., Lee, S. E., Kim, M., Cho, H., Choi, J., Lee, H., Hwang, K., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01720-4 · Cited by 57
Renard, E., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., Kovatchev, B. P., & iDCL Trial Research Group (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 51
Self-citationMonitoring of Pediatric Type 1 Diabetes
Marks, B. E., & Wolfsdorf, J. I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00128 · Cited by 71
“The guidelines recommend less stringent targets in patients who are unable to communicate their symptoms or who have hypoglycemia unawareness, recurrent severe hypoglycemia, lack of access to insulin analogs and advanced insulin delivery technology, or inability to regularly monitor BG levels (6, 7, 82).”
BackgroundMethodClinical recommendations for the use of the ambulatory glucose profile in diabetes care
Kröger, J., Reichel, A., Siegmund, T., & Ziegler, R. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819883032 · Cited by 51
“The expert group currently recommends a target for TIR of ≥70% for people with type 1 diabetes of all ages and for people with type 2 diabetes, which is in concordance with the newly published recommendation of the International Consensus on Time in Range.20 This target should be considered as a minimum requirement, s…”
ResultRiddell, M. C., Li, Z., Beck, R. W., Gal, R. L., Jacobs, P. G., Castle, J. R., Gillingham, M. B., Clements, M. A., Patton, S. R., Dassau, E., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0495 · Cited by 59
Self-citationAlharthi, S. K., Alyusuf, E. Y., Alguwaihes, A. M., Alfadda, A. A., & Al‐Sofiani, M. E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108682 · Cited by 56
Continuous Glucose Monitoring Use in Older Adults for Optimal Diabetes Management
Munshi, M. N. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0111 · Cited by 63
“However, it is important to recognize limitations of use of different types of CGM. Choosing the right CGM for the right patient improves the chance of successful use and better outcomes.”
InfluentialBoughton, C. K., Hartnell, S., Lakshman, R., Nwokolo, M., Wilinska, M. E., Ware, J., Allen, J. M., Evans, M. L., & Hovorka, R. (2023) · Diabetes Care · doi:10.2337/dc23-0728 · Cited by 60
Self-citationShamanna, P., Erukulapati, R. S., Shukla, A., Shah, L., Willis, B., Thajudeen, M., KOVIL, R. R., Baxi, R., Wali, M., Damodharan, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76584-7 · Cited by 72
Mattishent, K., Lane, K., Salter, C., Dhatariya, K., May, H. M., Neupane, S., & Loke, Y. K. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-032037 · Cited by 54
Seyed Ahmadi, S., Westman, K., Pivodic, A., Ólafsdóttir, A. F., Dahlqvist, S., Hirsch, I. B., Hellman, J., Ekelund, M., Heise, T., Polonsky, W., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2606 · Cited by 51
Self-citationPrahalad, P., Zaharieva, D. P., Addala, A., New, C., Scheinker, D., Desai, M., Hood, K. K., & Maahs, D. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00360 · Cited by 51
“Recent data indicate that glucose time-in-range (TIR) can also be a useful metric for families that correlate with HbA1c (49).”
BackgroundYu, Q., Jiang, J., Chen, Z., Han, C., Zhang, X., Yang, S., Zhou, P., Deng, T., & Yu, C. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.130898 · Cited by 52
Dovč, K., Lanzinger, S., Cardona‐Hernandez, R., Tauschmann, M., Marigliano, M., Cherubini, V., Preikša, R. T., Schierloh, U. H. E., Clapin, H. F., Aljaser, F., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.0077 · Cited by 56
Self-citationTauschmann, M., Cardona‐Hernandez, R., DeSalvo, D. J., Hood, K. K., Лаптев, Д. Н., Olinder, A. L., Wheeler, B. J., & Smart, C. E. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543156 · Cited by 82
“…value derived from CGM data over a de fi ned duration) [26], or most recently “ time in tight range ” [27] (the time spent within the 70 – 140 mg/ dL or 3.9 – 7.8 mmol/L range), have emerged as valuable clinical markers [28 – 30] with evidence for their clinical application still evolving [30, 31].”
InfluentialDi, J., Demanuele, C., Kettermann, A. E., Karahanoğlu, F. I., Cappelleri, J. C., Potter, A., Bury, D. P., Cedarbaum, J. M., & Byrom, B. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106661 · Cited by 63
de Kreutzenberg, S. V. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00524-7 · Cited by 53
“Data obtained from CGM have shown the significant improvement of several glycaemic indices, such as glucose time in range (TIR), time above range (TAR), time below range (TBR), and glucose variability [53, 54].”
BackgroundHerzig, D., Suhner, S., Roos, J., Schürch, D., Cecchini, L., Nakas, C. T., Weiss, S., Kadner, A., Kocher, G. J., Guensch, D. P., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0438 · Cited by 64
Self-citationContinuous glucose monitoring in cystic fibrosis – A practical guide
Chan, C. L., Ode, K. L., Granados, A., Moheet, A. A., Moran, A., & Hameed, S. A. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.025 · Cited by 51
Lu, J., Ma, X., Zhang, L., Mo, Y., Lu, W., Zhu, W., Bao, Y., Jia, W., & Zhou, J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108032 · Cited by 49
Self-citationKovatchev, B. P., Singh, H., Mueller, L., & Gonder-Frederick, L. A. (2022) · Diabetes Care · doi:10.2337/dc22-1217 · Cited by 49
“Similar analyses were conducted for all other secondary CGM-based and insulin delivery–based outcomes, which included the metrics recommended by the International Consensus on Time in Range (25): time <54 and <70 mg/dL, time >180 and >250 mg/dL, coefficient of variation, total daily insulin, and the number of user-ini…”
MethodSelf-citationEconomic burden of diabetes-related hypoglycemia on patients, payors, and employers
Shi, L., Fonseca, V. A., & Childs, B. P. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107916 · Cited by 54
Villard, O., Breton, M. D., Rao, S., Voelmle, M. K., Fuller, M. R., Myers, H. E., McFadden, R. K., Luke, Z. S., WAKEMAN, C. A., Oliveri, M. C., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0073 · Cited by 48
Wang, X. S., Dunlop, A. D., McKeen, J. A., Feig, D. S., & Donovan, L. (2023) · Diabetic Medicine · doi:10.1111/dme.15086 · Cited by 53
Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems
Hanson, K., Kipnes, M. S., & Tran, H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231225676 · Cited by 57
Eichenlaub, M., Pleus, S., Rothenbühler, M., Bailey, T. S., Bally, L., Brazg, R., Bruttomesso, D., Diem, P., Boija, E. E., Fokkert, M. J., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0465 · Cited by 55
Self-citationCeriello, A., de Valk, H. W., Guerci, B., Haak, T., Owens, D. R., Canobbio, M., Fritzen, K., Stautner, C., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108053 · Cited by 52
“is associated with significant benefits for people with diabetes [13].”
BackgroundInfluentialAraújo, D. B., Dantas, J. R., Silva, K. R., Souto, D. L., Pereira, M. D. F. C., Moreira, J. P. D. L., Luiz, R. R., Cláudio-da-Silva, C. S., Gabbay, M. A. L., Dib, S. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00993 · Cited by 51
“The percentage of glucose reading in time in range (TIR) established as 70–180 mg/dL was recorded (40).”
BackgroundPaldus, B., Morrison, D., Zaharieva, D. P., Lee, M. H., Jones, H., Obeyesekere, V. R., Lu, J., Vogrin, S., Gerche, A. L., McAuley, S. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1593 · Cited by 58
Ng, S. M., Wright, N. P., Yardley, D., Campbell, F., Randell, T. L., Trevelyan, N., Ghatak, A., & Hindmarsh, P. C. (2024) · BMC Medicine · doi:10.1186/s12916-024-03396-x · Cited by 58
“Analysis of data on metrics such as HbA1c, time in range (TIR), and frequency of hypoglycaemia was undertaken before the initiation of HCL, as well as at 3, 6, and 12 months post-commencement [8].”
MethodWyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf288 · Cited by 60
“In fact, the International Consensus on Time in Range noted in their recommendation that “ Recent data suggest that even more stringent targets and greater attention to overnight glucose profiles may be required …” (217).”
InfluentialDiabetes education in pediatrics: How to survive diabetes
Ergun-Longmire, B., Clemente, E. G., Maravolo, P. V., Roberts, C., Buth, K., & Greydanus, D. E. (2021) · Disease-a-Month · doi:10.1016/j.disamonth.2021.101153 · Cited by 54
Berget, C., Akturk, H. K., Messer, L. H., Vigers, T., Pyle, L., Snell‐Bergeon, J., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14441 · Cited by 46
“Additionally, there is a gap in the literature investigating what percentage of HCL use is necessary to realize glycaemic benefits in the real world, specifically the internationally recommended target of 70% TIR, which is endorsed by the American Diabetes Association (ADA) and many other professional diabetes organiz…”
BackgroundBarriers to Uptake of Insulin Technologies and Novel Solutions
PAULEY, M. E., Berget, C., Messer, L. H., & Forlenza, G. P. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s312858 · Cited by 73
GWAS of longitudinal trajectories at biobank scale
Ko, S., German, C., Jensen, A. E., Shen, J., Wang, A., Mehrotra, D. V., Sun, Y. V., Sinsheimer, J. S., Zhou, H., & Zhou, J. J. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.01.018 · Cited by 52
Burnside, M. J., Williman, J. A., Davies, H. M., Jefferies, C., Paul, R. G., Wheeler, B. J., Wiltshire, E. J., Anderson, Y. C., & de Bock, M. I. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100644 · Cited by 63
Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data
Lehmann, V., Föll, S., Maritsch, M., van Weenen, E., Kraus, M., Lagger, S., Odermatt, K., Albrecht, C., Fleisch, E., Zueger, T., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2290 · Cited by 53
“9 mmol/L (6), since early detection is clinically most relevant in enabling prompt treatment and preventing progression into more severe hypoglycemia.”
BackgroundListening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy
Lawton, J., Kimbell, B., Closs, M., Hartnell, S., Lee, T., Dover, A. R., Reynolds, R. M., Collett, C., Barnard-Kelly, K. D., Hovorka, R., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0323 · Cited by 56
Self-citationKang, J., Chen, Y., Zhao, Y., & Zhang, C. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2020.12.004 · Cited by 54
Ferstad, J. O., Vallon, J. J., Jun, D., Gu, A., Vitko, A., Morales, D. P., Leverenz, J., Lee, M. Y., Leverenz, B., Vasilakis, C., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13256 · Cited by 46
Danne, T., Limbert, C., Puig‐Domingo, M., Prato, S. D., Renard, É., Choudhary, P., & Seibold, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01114-x · Cited by 54
“Notably, 30% of the cohorts with TIR data reported clinically significant TIR improvements of 5% or more [13].”
BackgroundSelf-citationMo, Y., Wang, C., Lu, J., Shen, Y., Chen, L., Zhang, L., Lu, W., Zhu, W., Xia, T., & Zhou, J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109940 · Cited by 47
Li, J., Ma, J., Omisore, O. M., Liu, Y., Tang, H., Ao, P., Yan, Y., Wang, L., & Nie, Z. (2023) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2023.3279383 · Cited by 61
Graham, R., Müeller, L., Manning, M., HABIF, S., Messer, L. H., Pinsker, J. E., & Aronoff-Spencer, E. S. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0341 · Cited by 54
“13,14 The study also showed safety of autopopulation of CGM results into the bolus calculator, with no increased risk of hypoglycemia after boluses given with autopopulated CGM results versus manual entry of glucose values.”
InfluentialKarges, B., Rosenbauer, J., Stahl‐Pehe, A., Flury, M., Biester, T., Tauschmann, M., Lilienthal, E., Hamann, J., Galler, A., & Holl, R. W. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00284-5 · Cited by 63
Self-citationRichardson, K. M., Jospe, M. R., Bohlen, L. C., Crawshaw, J., Saleh, A. A., & Schembre, S. M. (2024) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-024-01692-6 · Cited by 57
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Evans, M., Hicks, D., Patel, D., Patel, V., McEwan, P. C., & Dashora, U. K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00728-6 · Cited by 48
Gawrecki, A., Zozulińska‐Ziółkiewicz, D., Michalak, M., Adamska, A., Michalak, M., Frąckowiak, U., Flotyńska, J., Pietrzak, M., Czapla, S., Gehr, B., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248965 · Cited by 53
“Moreover, the coefficient of variation remained constant throughout the study and was within the recommended range [30].”
BackgroundTime-in-range for monitoring glucose control: Is it time for a change?
Bellido, V., Pinés-Corrales, P. J., Villar‐Taibo, R., & Ampudia‐Blasco, F. J. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108917 · Cited by 52
Merino, J., Linenberg, I., Bermingham, K. M., Ganesh, S., Bakker, E., Delahanty, L. M., Chan, A. T., Capdevila Pujol, J., Wolf, J., Al Khatib, H., et al. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac026 · Cited by 46
Pasquel, F. J., Lansang, M. C., Khowaja, A., Urrutia, M. A., Cardona, S., Albury, B., Galindo, R. J., Fayfman, M., Davis, G., Migdal, A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1940 · Cited by 45
“In addition, glucose values obtained with CGMwere analyzed to compare the percentage of time that the sensor glucose measurement was below the target range (54–69mg/dL and,54mg/dL) (23).”
MethodGlucodensities: A new representation of glucose profiles using distributional data analysis
Matabuena, M., Petersen, A., Vidal, J. C., & Gude, F. (2021) · Statistical Methods in Medical Research · doi:10.1177/0962280221998064 · Cited by 82
Wakasugi, S., Mita, T., Katakami, N., Okada, Y., Yoshii, H., Osonoi, T., Nishida, K., Shiraiwa, T., Torimoto, K., Kurozumi, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001923 · Cited by 45
Levy, C. J., Kudva, Y. C., Özaslan, B., CASTORINO, K. N., O’Malley, G., Kaur, R. J., Levister, C. M., Church, M. M., Desjardins, D., MCCRADY-SPITZER, S. K., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0173 · Cited by 50
Self-citationPrahalad, P., Scheinker, D., Desai, M., Ding, V. Y., Bishop, F. K., Lee, M. Y., Ferstad, J. O., Zaharieva, D. P., Addala, A., Johari, R., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02975-y · Cited by 50
“…from CGM data review and contact based on clinical metrics (>1% of the time with level 2 hypoglycemia (<55 mg dl −1 ), >4% of the time with level 1 hypoglycemia (<70 mg dl −1 ), week-over-week decrease in TIR >15%, TIR 65% and wear time 50%, meeting targets) adapted from consensus guidelines 58 .”
14. Children and Adolescents: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s014 · Cited by 101
Self-citationCase series of a hybrid closed‐loop system used in pregnancies in clinical practice
Polsky, S., & Aktürk, H. K. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3248 · Cited by 48
“8 mmol/L).(16) This makes it more difficult to compare results of other systems previously studied in pregnancies to the 670G system case series we present here and it is a limitation of using the 670G system during pregnancy.”
ResultDiabetic Gastroparesis and Glycaemic Control
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1281-8 · Cited by 47
Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy
Yamamoto, J. M., & Murphy, H. R. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0667 · Cited by 52
Self-citationAutomated insulin delivery in older adults with type 1 diabetes
Kudva, Y. C., Henderson, R. J., Kanapka, L. G., Weinstock, R. S., Rickels, M. R., Pratley, R. E., Chaytor, N., Janess, K., Desjardins, D., Pattan, V., et al. (2025) · NEJM Evidence · doi:10.1056/evidoa2400200 · Cited by 45
Self-citationPemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
Ajjan, R. A., Heller, S. R., Everett, C. C., Vargas-Palacios, A., Higham, R., Sharples, L., Gorog, D. A., Rogers, A., Reynolds, C., Fernandez, C., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1219 · Cited by 44
Self-citationAndersen, A., Bagger, J. I., Sørensen, S. K., BALDASSARRE, M. P. A., Pedersen‐Bjergaard, U., Forman, J. L., Gislason, G., Lindhardt, T. B., Knop, F. K., & Vilsbøll, T. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01425-0 · Cited by 48
“The nomenclature varies between consensus reports [18, 19].”
Sebastián‐Valles, F., Alfonso, J. M., Martín, J. A. A., Jiménez‐Díaz, J., Alday, I. H., Navas-Moreno, V., Joya, T. A., García, M. D. M. F., Gómez, G. L. R., Hierro, J. G., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03254-w · Cited by 50
Hengist, A., Davies, R. G., Walhin, J., Buniam, J., Merrell, L. H., Rogers, L. M., Bradshaw, L., Moreno‐Cabañas, A., Rogers, P. J., Brunstrom, J. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101667 · Cited by 68
Ageing well with diabetes: the role of technology
Maltese, G., McAuley, S. A., Trawley, S. L., & Sinclair, A. J. (2024) · Diabetologia · doi:10.1007/s00125-024-06240-2 · Cited by 63
“For this ‘high-risk’ group, the authors recommend a less stringent TIR (3.9–10.0 mmol/l glucose) target of >50% (vs >70% in general recommendations) and a TBR ( 3.9 mmol/l glucose) target of 1% (vs 4% in general recommendations) [49], irrespective of frailty and functional status.”
BackgroundInfluentialToffanin, C., Kozak, M., Sumnik, Z., Cobelli, C., & Petruzelkova, L. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0375 · Cited by 44
Self-citationPetruželková, L., Jiranova, P., Šoupal, J., Kozak, M., Plachý, L., Neuman, V., Průhová, Š., Obermannová, B., Koloušková, S., & Šumník, Z. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13190 · Cited by 46
“8 mmol/L) in school children, this finding still does not exceed the values recommended by a panel of experts.(32) Indeed, borderline asymptomatic glycemia with a favorable trend is not always corrected F IGURE 2 Comparison of answers to the “Closed-Loop Experience Questionnaire” (27) provided by the parents/caregiver…”
BackgroundMethodInfluentialAiello, E. M., Deshpande, S., Özaslan, B., Wolkowicz, K. L., Dassau, E., Pinsker, J. E., & Doyle, F. J. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100312 · Cited by 49
Self-citationTornese, G., Buzzurro, F., Carletti, C. V., Faleschini, E., & Barbi, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.766314 · Cited by 48
“When considering recommended target (TIR >70%) (27), the users of a-HCL attained this target earlier (63% at the beginning of a-HCL use) and more stably (54% after six months), compared to s-HCL (40% at the beginning and 25% after six months).”
Challenges and Opportunities in Using Telehealth for Diabetes Care
Crossen, S. S., Bruggeman, B., Haller, M. J., & Raymond, J. K. (2022) · Diabetes Spectrum · doi:10.2337/dsi21-0018 · Cited by 50
Borel, A.-L., Lablanche, S., Waterlot, C., Joffray, E., Barra, C., Arnol, N., Amougay, H., & Benhamou, P.-Y. (2024) · Diabetes Care · doi:10.2337/dc24-0623 · Cited by 43
Time in range in pregnancy: is there a role?
Wyckoff, J. A., & Brown, F. M. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0103 · Cited by 39
Hohendorff, J., Gumprecht, J., Mysliwiec, M., Zozulinska-Ziolkiewicz, D., & Malecki, M. T. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0034 · Cited by 43
GluGAN: Generating Personalized Glucose Time Series Using Generative Adversarial Networks
Zhu, T., Li, K., Herrero, P., & Georgiou, P. (2023) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2023.3271615 · Cited by 56
Garcia‐Tirado, J., Colmegna, P. H., Villard, O., Diaz, J. L., Esquivel-Zuniga, R., Koravi, C. L. K., Barnett, C. L., Oliveri, M. C., Fuller, M. R., Brown, S. A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0119 · Cited by 50
“FCL and FCL1 provided TIR above the ADA-recommended threshold of 70% overall (15) without any carbohydrate announcement over a 24-h period and using a single-hormone system in a structured hotel-based study.”
MethodCriego, A. B., Carlson, A. L., Brown, S. A., Forlenza, G. P., Bode, B. W., Levy, C. J., Hansen, D. W., Hirsch, I. B., Bergenstal, R. M., Sherr, J. L., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0364 · Cited by 49
Self-citationMo, Y., Lu, J., & Zhou, J. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14112 · Cited by 56
“Subsequently, time in range (TIR) emerged as the single most important CGM metric, which was recommended widely and supported by a series of studies 7,8 .”
BackgroundMethodInfluentialCOVID-19, type 1 diabetes, and technology: why paediatric patients are leading the way
Danne, T., & Limbert, C. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30155-8 · Cited by 43
“8, 9 These targets must also be communicated during remote care.”
BackgroundSelf-citationSandig, D., Grimsmann, J., Reinauer, C., Melmer, A., Zimny, S., Müller-Korbsch, M., Forestier, N., Zeyfang, A., Bramlage, P., Danne, T., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0019 · Cited by 43
“Our definition of ‘‘continuous’’ glucose monitoring as at least 50% of the 24-h period to be documented is more conservative than the international consensus recommendation ( > 70%), 13 but of course somewhat arbitrary.”
Self-citationHerrero, P., Alalitei, A., Reddy, M., Georgiou, P., & Oliver, N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0387 · Cited by 43
“These results support the consensus metrics for CGM analysis 2,3 and are consistent with an analysis suggesting that MAG was the most discriminant metric for glycemic variability and that time in range 70–180 mg/dL was the most robust target range metric.”
Cobry, E. C., Berget, C., Messer, L. H., & Forlenza, G. P. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0055 · Cited by 44
Braune, K., Boß, K., Schmidt-Herzel, J., Gajewska, K. A., Thieffry, A., Schulze, L., Posern, B., & Raile, K. (2021) · JMIR mhealth and uhealth · doi:10.2196/24374 · Cited by 55
“Our findings support the fact that there is a need to use CGM-derived outcome measures in clinical care and clinical research and a need to identify new surrogate markers for the development of diabetes-related long-term complications [67-69].”
BackgroundResultCarlson, A. L., Kanapka, L. G., Miller, K. M., Ahmann, A. J., Chaytor, N. S., Fox, S., Kiblinger, L., Kruger, D., Levy, C. J., Peters, A. L., et al. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819894974 · Cited by 43
“Glucose metrics derived from international consensus reports were calculated for the 203 participants using the blinded CGM data from the screening period, including % time <70 mg/dL, % time <54 mg/dL, % time in range (70-180 mg/dL), % time >180 mg/dL, % time >250 mg/dL, and coefficient of variation (CV).(28,29) The %…”
BackgroundMethodResultDanne, T. P. A., Joubert, M., Hartvig, N. V., Kaas, A., Knudsen, N. N., & Mader, J. K. (2024) · Diabetes Care · doi:10.2337/dc23-2176 · Cited by 42
Self-citationGarcía‐Hermoso, A., Ezzatvar, Y., Huerta‐Uribe, N., Alonso-Martínez, A. M., Chueca-Guindulain, M. J., Berrade‐Zubiri, S., Izquierdo, M., & Ramírez‐Vélez, R. (2022) · European Journal of Sport Science · doi:10.1080/17461391.2022.2086489 · Cited by 57
“Time in range (within target range, below range, above range) is also appropriate and a useful clinical target that complements HbA1c (Battelino et al., 2019).”
BackgroundDiabetes Technology Use in Adults with Type 1 and Type 2 Diabetes
Kravarusic, J., & Aleppo, G. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.10.006 · Cited by 42
Effects of Cardiovascular Risk Factor Variability on Health Outcomes
Lee, S., Kim, M. K., & Rhee, E. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.217 · Cited by 47
“According to the International Consensus on Use of CGM, stable glucose levels are defined as a coefficient of variation <36% and unstable glucose levels are defined as a coefficient of variation ≥36% [76].”
MethodBrain Health in Children with Type 1 Diabetes: Risk and Protective Factors
Jaser, S. S., & Jordan, L. C. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01380-w · Cited by 67
Rodbard, D. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14906 · Cited by 47
Self-citationEmerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases
ALMURASHI, A. M., Rodriguez, E., & Garg, S. K. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00348-3 · Cited by 67
Self-citationKong, A. P. S., Lim, S. K., Yoo, S.-H., Ji, L., Chen, L., Bao, Y., Yeoh, E. C. K., Chan, S.-P., Wang, C., Mohan, V., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110718 · Cited by 49
Olsen, M. T., Klarskov, C. K., Jensen, S. H., Rasmussen, L. M., Lindegaard, B., Andersen, J. A., Gottlieb, H., Lunding, S., Pedersen‐Bjergaard, U., Hansen, K. B., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2222 · Cited by 47
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.